MetaCap

Protalix BioTherapeutics Inc. (DE) Company Profile

NYSE: PLXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.90-0.16 (-5.23%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Protalix BioTherapeutics (DE) at a glance

Protalix BioTherapeutics Inc. (DE) (NYSE: PLX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Hackensack, NJ, Israel. Protalix BioTherapeutics (DE) is led by Mr. Dror Bashan and employs about 226 people. At a market capitalization of $244.5 million, it is considered a small-cap company.

Its SEC Central Index Key (CIK) is 0001006281, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Protalix BioTherapeutics (DE) do?

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.

Business description based on the company's public filings.

Company information

Legal name
Protalix BioTherapeutics Inc. (DE)
Ticker
NYSE: PLX
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Dror Bashan
Employees
226
Headquarters
2 University Plaza, Hackensack, NJ, Israel
Phone
201 696 9345
Market cap
$244.52M
SEC CIK
0001006281
Latest annual report
10-K · Mar 18, 2026

Companies similar to Protalix BioTherapeutics (DE)

PLX peer companies
CompanyPrice% ChgMarket capCompare
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs PLX
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs PLX
EDITEditas Medicine Inc.1.64-4.09%$253.12Mvs PLX
SABSSAB Biotherapeutics Inc.2.81-3.44%$253.15Mvs PLX
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs PLX
SCTXScribe Therapeutics Inc.12.07-8.70%$228.58Mvs PLX
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs PLX
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs PLX

Related